Literature DB >> 18519659

Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy.

Stefan Ambs1, Francesco M Marincola, Magdalena Thurin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18519659     DOI： 10.1158/0008-5472.CAN-08-0521

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  4 in total

Review 1.  Turning laboratory findings into therapy: a marathon goal that has to be reached.

Authors:  Beatrix Kotlan; David F Stroncek; Francesco M Marincola
Journal:  Pol Arch Med Wewn       Date:  2009-09

2.  RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Authors:  Kilian M Gust; Matthias D Hofer; Sven R Perner; Robert Kim; Arul M Chinnaiyan; Sooryanarayana Varambally; Peter Moller; Ludwig Rinnab; Mark A Rubin; Jochen Greiner; Michael Schmitt; Rainer Kuefer; Mark Ringhoffer
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

Review 3.  Biomarkers in T cell therapy clinical trials.

Authors:  Michael Kalos
Journal:  J Transl Med       Date:  2011-08-19       Impact factor: 5.531

4.  Biological convergence of cancer signatures.

Authors:  Xavier Solé; Núria Bonifaci; Núria López-Bigas; Antoni Berenguer; Pilar Hernández; Oscar Reina; Christopher A Maxwell; Helena Aguilar; Ander Urruticoechea; Silvia de Sanjosé; Francesc Comellas; Gabriel Capellá; Víctor Moreno; Miguel Angel Pujana
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.